Skip to search formSkip to main contentSkip to account menu

afuresertib

An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Afuresertib… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

GSK2110183

Broader (2)

PyrazolesThiophenes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Screening of PI3K-Akt-targeting Drugs for Silkworm against Bombyx mori Nucleopolyhedrovirus
Bombyx mori nucleopolyhedrovirus (BmNPV) is the most prevalent threat to silkworms. Hence, there is a need for antiviral agents… 
2018
2018
A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)*
Abstract AKT plays a centralized role in tumor proliferation and survival and is aberrantly activated in chronic lymphocytic… 
2018
2018
Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma.
Afuresertib (AFU), a novel inhibitor of the serine/threonine kinase AKT, has clinical efficacy as a monotherapy against… 
2016
2016
Phase I/II dose-escalation and expansion study of afuresertib + carboplatin and paclitaxel in recurrent ovarian cancer.
2551Background: Patients (pts) with ovarian cancer (OC) often develop resistance to standard medical treatment (Rx) with platinum… 
2015
2015
A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)
Introduction: Ofatumumab is an anti-CD20 monoclonal antibody with single-agent responses of 47-58% in refractory CLL (Wierda et… 
2014
2014
3 Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer
2014
2014
Afuresertib Shows Activity Against Multiple Myeloma
In a phase I trial, the oral AKT inhibitor afuresertib demonstrated single-agent activity against hematologic malignancies… 
2014
2014
A key to the quest?
In this issue of Blood , Spencer et al report on the phase 1 study results of the novel AKT inhibitor afuresertib, which showed… 
2014
2014
Afuresertib: Protein kinase B (PKB) inhibitor oncolytic
2013
2013
An Open-Label Phase 2 Study Of Ofatumumab In Combination With a Novel AKT Inhibitor (Afuresertib) In Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)
Introduction Ofatumumab is a novel anti-CD20 monoclonal antibody which led to impressive single-agent responses of 47-58% in a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)